Cargando…

Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC

Pancreatic Ductal Adenocarcinoma (PDAC) is one of the deadliest solid tumors and is estimated to become a leading cause of cancer-related death in coming years. Despite advances in surgical approaches and the emergence of new chemotherapy options, its poor prognosis has not improved in the last deca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Digiacomo, Graziana, Volta, Francesco, Garajova, Ingrid, Balsano, Rita, Cavazzoni, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400856/ https://www.ncbi.nlm.nih.gov/pubmed/34440587 http://dx.doi.org/10.3390/life11080843

Ejemplares similares

It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer
por: Garajová, Ingrid, et al.
Publicado: (2022)

Role of Cytokines and Other Soluble Factors in Tumor Development: Rationale for New Therapeutic Strategies
por: Cavazzoni, Andrea, et al.
Publicado: (2023)

PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition
por: Cretella, Daniele, et al.
Publicado: (2019)

Small Bowel Adenocarcinoma: From Molecular Insights to Clinical Management
por: Gelsomino, Fabio, et al.
Publicado: (2022)

The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review
por: Schipilliti, Francesca Matilde, et al.
Publicado: (2021)

Transforming Growth Factor-Beta Signaling in Cancer-Induced Cachexia: From Molecular Pathways to the Clinics
por: Balsano, Rita, et al.
Publicado: (2022)

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
por: Digiacomo, Graziana, et al.
Publicado: (2022)

The implication of liquid biopsies to predict chemoresistance in pancreatic cancer
por: Pietri, Elisabetta, et al.
Publicado: (2021)

Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
por: Comandatore, Annalisa, et al.
Publicado: (2022)

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib
por: La Monica, Silvia, et al.
Publicado: (2020)

Targeting KRAS in PDAC: A New Way to Cure It?
por: He, Qianyu, et al.
Publicado: (2022)

The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC
por: Brown, Matthew, et al.
Publicado: (2020)

Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment?
por: Papadakos, Stavros P., et al.
Publicado: (2022)

Emerging Potential Mechanism and Therapeutic Target of Ferroptosis in PDAC: A Promising Future
por: Li, Chang, et al.
Publicado: (2022)

Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing
por: Hua, Yu, et al.
Publicado: (2023)

Genetic and biological hallmarks of colorectal cancer
por: Li, Jiexi, et al.
Publicado: (2021)

Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies
por: Reyes-Castellanos, Gabriela, et al.
Publicado: (2020)

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2019)

The Microbiome in PDAC—Vantage Point for Future Therapies?
por: Pfisterer, Nina, et al.
Publicado: (2022)

Complement and Fungal Dysbiosis as Prognostic Markers and Potential Targets in PDAC Treatment
por: Speth, Cornelia, et al.
Publicado: (2022)

Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
por: Orth, Michael, et al.
Publicado: (2019)

CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells
por: Terenziani, Rita, et al.
Publicado: (2022)

Hallmarks of cancer and hallmarks of aging
por: Blagosklonny, Mikhail V.
Publicado: (2022)

Hallmarks of cancer—the new testament
por: Senga, Sasi S., et al.
Publicado: (2021)

Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells
por: Bonelli, Mara, et al.
Publicado: (2020)

BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC
por: Jauset, Toni, et al.
Publicado: (2018)

Regulatory role of RNA modifications in the treatment of pancreatic ductal adenocarcinoma (PDAC)
por: Chen, Hao, et al.
Publicado: (2023)

A Simple Overview of Pancreatic Cancer Treatment for Clinical Oncologists
por: Garajová, Ingrid, et al.
Publicado: (2023)

Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC
por: Alhothali, Marwa, et al.
Publicado: (2019)

The EPH/Ephrin System in Pancreatic Ductal Adenocarcinoma (PDAC): From Pathogenesis to Treatment
por: Papadakos, Stavros P., et al.
Publicado: (2023)

Modifiable Pancreatic Ductal Adenocarcinoma (PDAC) Risk Factors
por: Michalak, Natalia, et al.
Publicado: (2023)

Scaling the immune incline in PDAC
por: Rojas, Luis A., et al.
Publicado: (2021)

The biological implications of Yin Yang 1 in the hallmarks of cancer
por: Meliala, Ian Timothy Sembiring, et al.
Publicado: (2020)

Should patients on levothyroxine therapy be screened for pancreatic cancer?
por: Garajová, Ingrid, et al.
Publicado: (2022)

Transverse Space Charge Effect During Bunch Compression in PDAC1 and PDAC2 Compressor Ring
por: Franchetti, Giuliano
Publicado: (2000)

Loss of FGFR4 promotes the malignant phenotype of PDAC
por: D’Agosto, Sabrina, et al.
Publicado: (2022)

Combatting PDAC with two tumor-targeting small RNAs
por: Kasinski, Andrea L.
Publicado: (2019)

Synchronous and metachronous colorectal liver metastases: impact of primary tumor location on patterns of recurrence and survival after hepatic resection
por: Garajova, Ingrid, et al.
Publicado: (2021)

Interdisciplinary Approach of Establishing PDAC Resectability: Biochemical, Radiological and NAT Regimen Prognostic Factors—Literature Review
por: Gulla, Aiste, et al.
Publicado: (2022)

Autophagy is required for PDAC glutamine metabolism
por: Seo, Ju-Won, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_62t20pj905ngemg3d1vr0fjj1e